All
RWC 2025: Update on the VERONA trial for diabetic macula edema
Q&A: Alan J. Franklin, MD, PHD, speaks to the use of intraoperative fluorescein angiography
RWC 2025: Updates on the HELIOS trial for diabetic retinopathy
At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs).
Optigo Bio receives People’s Choice Award for its proprietary drug anchoring
Optigo Biotherapeutics presents promising preclinical data at ARVO.
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.
Phase 2 DAWN for XLRP data presented at ARVO 2025
Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.
Assessment of AI-enabled screening for ROP in low-resource settings
Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.
Alkeus Pharmaceuticals presents additional data from Phase 2 clinical SAGA study for GA
Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.
Positive interim pilot clinical trial results of PYK-2101
Pykus Therapeutics reveals promising results for PYK-2101, a retinal sealant that enhances recovery and improves patient experience in retinal detachment surgery.
Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME
The recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.
ARVO 2025: Carl Danzig, MD, recaps the first stage of a phase 3 study of drop-based DME therapy
According to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.
Topcon announces launch of IDHea
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.
Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101
The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.
Phase 2 BETTER trial results shared at ARVO 2025
Innovent Biologics announced latest data on IBI302
The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting.
Repeated anti-VEGF injections do not cause vascular issue in patients with AMD
Subrata Batabyal, PhD, receives 2025 Carl Camras Translational Research Award from ARVO Foundation
Dr. Subrata Batabyal earns the 2025 Carl Camras Award for innovative optogenetic therapies, advancing vision restoration for inherited retinal diseases.
ARVO 2025: Early intervention is crucial for patients with sickle cell retinopathy
Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.
Subretinal drusenoid deposits: Marker for unrecognized cardiac disease
New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.
OPGX-LCA5 gene therapy phase 1/2 data support potential to restore meaningful vision
Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.
Positive 36-week results shared from the Phase 2b ASPIRE for DME
The complete 36-week results of the Phase 2b ASPIRE study saw non-inferior visual gains in Best-Corrected Visual Acuity compared to a leading anti-VEGF product.
ANI Pharmaceuticals announces data on use of Cortrophin Gel
The preclinical data was presented during the 2025 ARVO meeting.
RetinalGenix signs new laboratory lease with MBC BioLabs
The Retinal Genix plans to use the facility to further the development of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform.
ARVO 2025: Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.
ARVO 2025: Rishi Singh, MD, discusses real-world clinical outcomes in patients with DME
In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.
J&J gene therapy treatment fails primary endpoints
The LUMEOS phase 3 clinical trial resulted in botaretigene sparoparvovec not meeting primary endpoints to improve visual navigation of XLRP.
Results from preclinical study KIO-104 released
KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.
First patient dosed in VAN-2401 phase 1 clinical trial
The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.
4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema
4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.
ARVO Foundation to give Subrata Batabyal, PhD, 2025 Carl Camras Translational Research Award
